Tekla Capital Management’s Acceleron Pharma XLRN Stock Holding History

Tekla Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40,606	Closed	-$3.87M	–	227
2020 Q2	$3.87M	Hold	40,606	–	–	0.15%	113
2020 Q1	$3.65M	Sell	40,606 -45,707	-53%	-$3.55M	0.17%	104
2019 Q4	$4.58M	Hold	86,313	–	–	0.17%	110
2019 Q3	$3.41M	Sell	86,313 -102,075	-54%	-$4.43M	0.15%	106
2019 Q2	$7.74M	Hold	188,388	–	–	0.32%	71
2019 Q1	$8.77M	Buy	188,388 +17,622	+10%	+$774K	0.36%	62
2018 Q4	$7.44M	Hold	170,766	–	–	0.32%	65
2018 Q3	$9.77M	Hold	170,766	–	–	0.35%	66
2018 Q2	$8.29M	Sell	170,766 -102,332	-37%	-$3.73M	0.31%	73
2018 Q1	$10.7M	Sell	273,098 -10,285	-4%	-$437K	0.42%	53
2017 Q4	$12M	Buy	283,383 +223,729	+375%	+$8.39M	0.46%	47
2017 Q3	$2.23M	Hold	59,654	–	–	0.08%	115
2017 Q2	$1.81M	Buy	59,654 +5,204	+10%	+$151K	0.07%	115
2017 Q1	$1.44M	Hold	54,450	–	–	0.06%	119
2016 Q4	$1.39M	Buy	+54,450	New	+$1.73M	0.06%	117

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Tekla Capital Management's XLRN Position: Q3 2020 in Review

Tekla Capital Management sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 40,606 shares — an estimated $3.87M sold.

Tekla Capital Management first reported a position in XLRN in Q4 2016 and held it in 15 quarters. The position peaked at $12M in Q4 2017. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Tekla Capital Management reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 40,606 Acceleron Pharma shares in Q3 2020, an estimated $3.87M.
Tekla Capital Management first reported a position in Acceleron Pharma in Q4 2016 and held it in 15 quarters.
Tekla Capital Management's Acceleron Pharma position peaked at $12M in Q4 2017.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.